UCB SA (UCB.BR)

118,70 -1,30 (-1,08%) A partir del 10:57AM CEST. Mercado abierto.

UCB SA

Allée de la Recherche, 60
Brussels 1070
Belgium
32 2 559 99 99
https://www.ucb.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 8450

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Jean-Christophe Tellier	CEO & Executive Director	4,1M	N/A	1959
Ms. Sandrine Dufour CFA	Executive VP, CFO & Chief Corporate Development	N/A	N/A	1966
Dr. Kirsten Lund-Jurgensen Ph.D.	Executive Vice President of Supply & Technology Solutions	N/A	N/A	1960
Dr. Dhavalkumar D. Patel M.D., Ph.D.	Executive VP & Chief Scientific Officer	N/A	N/A	1961
Ms. Denelle J. Waynick Johnson J.D.	Executive VP & General Counsel	N/A	N/A	1967
Mr. Jean-Luc Fleurial	Executive VP & Chief Human Resources Officer	N/A	N/A	1965
Prof. Iris Low-Friedrich	Executive VP & Chief Medical Officer	N/A	N/A	1960
Mr. Emmanuel Caeymaex	Executive VP of Immunology Solutions & Head of US	N/A	N/A	1969
Ms. Caroline Vancoillie	Chief Accounting Officer, Head of Group Finance & CFO of Patient Value Functions	N/A	N/A	N/A
Antje Witte	Head of Investor Relations	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Gobierno corporativo

El ISS Governance QualityScore de UCB SA, a día 1 de abril de 2024, es 3. Las puntuaciones base son Auditoría: 1; Tablero: 4; Derechos de los accionistas: 1; Compensación: 5.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.